Diabetes news cocktail therapy and ada2015

Liu Yanjun, No.306 Hospital of PLA, PLA Center for diabetes, forwarding Bio Valley

Nordisk launched in the UK cocktail Xultophy with diabetes, hypoglycemic and anti obesity

(Novo Nordisk) diabetes giant Novo Nordisk recently announced the launch of diabetes cocktail Xultophy in Britain (IDegLira), which is the company following the beginning of this year in Switzerland and Germany successfully launched Xultophy third EU countries. Xultophy is the world’s first long-acting insulin and GLP-1 receptor agonist compound preparation, both hypoglycemic and weight loss, for the majority of people with type 2 diabetes is a great gospel! The industry believes that Xultophy will become a Nordisk blockbuster products, annual peak sales will exceed $1 billion.

Xultophy is an injection once a day, a long-acting insulin Tresiba (insulin degludec, degludec) and glucagon like peptide 1 (GLP-1) receptor agonist Victoza (liraglutide, liraglutide), which can stimulate the natural secretion of insulin.

Victoza (liraglutide, 1.8mg) is the annual sales of $2 billion, blockbuster products, market leader in GLP-1. In clinical trials, liraglutide not only significantly improved glycemic control, but also effective weight loss and improve obesity related comorbidities. Dujuhuiyan Novo Nordisk, according to this finding will develop liraglutide as a weight loss of Saxenda injection (liraglutide, liraglutide, 3mg), and liraglutide also became the first global development for weight management GLP-1 receptor agonist, the needle weight loss has been the United States, EU and Canada, approved. The industry believes that Saxenda’s annual sales peak will reach $1 billion 500 million.

in the European Union, Xultophy approved in September 2014 for the treatment of adult patients with type 2 diabetes mellitus, indications for oral hypoglycemic drugs alone or in combination with insulin but poor glycemic control in type 2 diabetes group. The clinical data showed that the basal insulin therapy in poorly controlled patients with type 2 diabetes, glycosylated hemoglobin Xultophy (HbA1c) level was significantly decreased by 1.9%, with an average of 2.7 kg of weight loss, while the probability of hypoglycemia compared with the Tresiba.

at present, Xultophy in the European market prospects for a bright, from the beginning of the sale of German and Swiss sales performance, the drug has been;